Dreem Health, a digital sleep clinic managed by The Sunrise Group, announced a partnership with Humana to increase the health insurer’s members’ access to Dreem Health’s sleep technologies and services.
Humana members will have coverage for Dreem Health’s digital clinic offerings, which includes digital testing and diagnosing patients with sleep disorders, including sleep apnea, insomnia and restless leg syndrome. Members can also use Sunrise’s proprietary at-home sleep tests and treatments.
In addition to Humana, Dreem Health is currently part of a network that includes Aetna, UnitedHealthcare, Cigna, Anthem, Blue Cross Blue Shield, Medicare, and Health Net of California.
The announcement follows Sunrise’s acquisition of Dreem Health’s management in 2024.
“Everyone deserves access to better sleep care, and cost can be a serious barrier in getting the sleep care you need,” Laurent Martinot, founder and CEO of Sunrise, told MobiHealthNews.
“This partnership with Humana not only legitimizes our mission to close this gap, but also provides a frictionless, affordable path forward for Humana members. Twenty-four percent of people seek sleep solutions but don’t know where to turn. With partnerships like this, we’re pushing forward on our path to making high-quality sleep care accessible to all.”
THE LARGER TREND
In 2024, Sunrise acquired Dreem Health. The aim was to “democratize and accelerate” access to sleep care by integrating Sunrise’s proprietary diagnostic technology with Dreem Health’s partnerships with major insurers and Medicare.
That same year, Laurent Martinot, CEO and cofounder of Sunrise, told MobiHealthNews that one of the biggest developments in the sleep health world is the growing evidence that the use of GLP-1s can help treat sleep apnea.
“Researchers have confirmed that weight loss is particularly beneficial for obese patients with sleep apnea, so looking ahead to 2025, I believe we will continue to see widespread use of anti-obesity medications as a major treatment for patients who struggle with obesity and sleep apnea,” Martinot said.
In 2023, Sunrise received FDA 510(k) clearance for its home sleep apnea test that’s placed on a user’s chin at night.
The test uses a sensor that analyzes bio-signals from mandibular jaw movements, which can help calculate respiratory disturbance frequently found in sleep apnea patients.
In addition, it evaluates airflow and oximetry during sleep to aid in diagnosing sleep-related breathing disorders and sleep apnea. Results are then sent to an AI-enabled app that analyzes the data, which users can share with a healthcare provider via an online portal.
